<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373918</url>
  </required_header>
  <id_info>
    <org_study_id>10-001714</org_study_id>
    <nct_id>NCT01373918</nct_id>
  </id_info>
  <brief_title>Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders</brief_title>
  <official_title>Low Dose Parenteral Fat for the Prevention of Parenteral Nutrition Associated Cholestasis in Neonates With Congenital/Acquired Gastrointestinal Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonates with congenital/acquired gastrointestinal disorders are at high risk for Parenteral
      Nutrition Associated Cholestasis (PNAC). Besides enteral nutrition, standard therapies to
      prevent and treat PNAC have been limited and marginal. Recently, the dose and composition of
      standard intravenous fat emulsions have implicated in the development and progression of
      PNAC.

      In this study, neonates with congenital/acquired gastrointestinal disorders will be
      randomized, in a unblinded fashion, to receive either the standard dose of an intravenous
      omega-6 fatty acid emulsion or a low dose of an intravenous omega-6 fatty acid emulsion
      throughout their course of PN or until hospital discharge, death or 100 days of life,
      whichever comes first. The primary outcome will be the presence of cholestasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parenteral Nutrition (PN) acts as an intravenous source of both macronutrients and
      micronutrients when enteral feeds are not possible. Intravenous fat emulsions often
      supplement PN and provide a dense source of non-protein calories and essential fatty acids.
      Although PN is life-sustaining, it is associated with a myriad of life-threatening
      complications including Parenteral Nutrition Associated Cholestasis (PNAC). Children
      dependent on PN for an extended period of time are high risk for liver failure.

      The etiology of PNAC remains poorly understood. Neonates with congenital and acquired
      gastrointestinal disorders are at high risk for PNAC and its subsequent complications.
      Examples of these gastrointestinal disorders include gastroschisis, volvulus, atresias,
      dysmotility and malabsorption disorders, pseudo-obstruction, and Hirschsprung's disease.
      These disorders often render the gut non-functional for extended periods of time. As a
      result, these patients become PN-dependent and develop PNAC.

      Specific PN components have been implicated in the pathogenesis of PNAC. More recently,
      standard intravenous fat emulsions have been labeled as one of the main culprits contributing
      to PNAC. Standard intravenous fat emulsions are dosed as high as 4 g/kg/d and are derived
      from soybean and/or safflower oil, which are rich in omega-6 fatty acids and phytosterols and
      contain a paucity of omega-3 fatty acids. It is unclear if the dose or high omega-6 fatty
      acid:omega-3 fatty acid ratio and phytosterols is responsible for the development of PNAC.

      The primary specific aim of this study is to determine if PNAC is related to the amount of
      standard intravenous fat emulsion administered to neonates with congenital/acquired
      gastrointestinal disorders. The investigators hypothesize that the PNAC is unrelated to the
      dose of intravenous fat emulsions. To test this hypothesis, neonates with congenital/acquired
      gastrointestinal disorders will be randomized to low dose standard soybean based parenteral
      fat, 1 g/kg/d, or standard dose soybean parenteral fat, 3 g/kg/d. Secondary outcomes include:
      mortality rate, length of stay, and anthropometric measurements at 28 days of life and at the
      end of the hospital stay, which is expected to be an average of 5 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to slow enrollment.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Cholestasis</measure>
    <time_frame>prior to 100 days of life, hospital discharge, or death whichever comes first</time_frame>
    <description>Cholestasis will be defined by a direct bilirubin &gt; 2 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>at the end of the hospital stay which is expected to be an average of 5 weeks</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurements</measure>
    <time_frame>28 days of age</time_frame>
    <description>Growth will be assessed by growth velocity at 28 days of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric Measurements</measure>
    <time_frame>approximately 5 weeks</time_frame>
    <description>Growth will be assessed by weight at the time of hospital discharge (approximately 5 weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>low dose intravenous fat emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose intravenous fat emulsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
    <arm_group_label>low dose intravenous fat emulsion</arm_group_label>
    <other_name>soybean oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
    <arm_group_label>standard dose intravenous fat emulsion</arm_group_label>
    <other_name>soybean oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  congenital or acquired gastrointestinal disorder

          -  age less than 5 days of life

        Exclusion Criteria:

          -  congenital intrauterine infection know to be associated with liver involvement

          -  known structural liver abnormalities

          -  known genetic disorders (trisomy 21, 13, and 18)

          -  inborn errors of metabolism

          -  infants meeting the criteria for terminal illness (ph:6.8&gt;2 hours)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara L Calkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>May 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2016</results_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Kara L. Calkins, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cholestasis</keyword>
  <keyword>neonates</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>gastrointestinal disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>Fat Emulsions, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>41 subjects were enrolled in the study. Only subjects who required &gt; 14 days of parenteral nutrition and who had an abdominal surgery were included in the final analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
        <group group_id="B2">
          <title>Standard Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="1.4"/>
                    <measurement group_id="B2" value="1.3" spread="1.1"/>
                    <measurement group_id="B3" value="1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of Cholestasis</title>
        <description>Cholestasis will be defined by a direct bilirubin &gt; 2 mg/dL</description>
        <time_frame>prior to 100 days of life, hospital discharge, or death whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Cholestasis</title>
          <description>Cholestasis will be defined by a direct bilirubin &gt; 2 mg/dL</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of Cholestasis-Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of Cholestasis-No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <description>death</description>
        <time_frame>at the end of the hospital stay which is expected to be an average of 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <description>death</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anthropometric Measurements</title>
        <description>Growth will be assessed by growth velocity at 28 days of age</description>
        <time_frame>28 days of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Anthropometric Measurements</title>
          <description>Growth will be assessed by growth velocity at 28 days of age</description>
          <units>g/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="8"/>
                    <measurement group_id="O2" value="24" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anthropometric Measurements</title>
        <description>Growth will be assessed by weight at the time of hospital discharge (approximately 5 weeks)</description>
        <time_frame>approximately 5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Intravenous Fat Emulsion</title>
            <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Anthropometric Measurements</title>
          <description>Growth will be assessed by weight at the time of hospital discharge (approximately 5 weeks)</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.9"/>
                    <measurement group_id="O2" value="3.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Til hospital discharge, which is an average of approximately 5 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose Intravenous Fat Emulsion</title>
          <description>Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
Intralipid: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kara L. Calkins</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310 825-9330</phone>
      <email>KCalkins@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

